Medivir presented its cathepsin K program at the ongoing 31st ASBMR meeting in Denver, USA

Medivir presented preclinical data on two candidate drugs (MIV-710, MIV-711) from its cathepsin K inhibitor program in a poster session during the ASBMR (American Society for Bone and Mineral Research) meeting. The conclusions highlighted in the presentation: The candidate drugs described are potent and highly selective inhibitors of human cat K in vitro. The advantageous lysosomotropic properties of these compounds resulted in enhanced potency in an osteoclast cell-based assay (Fuller et al., 2009) without any loss of selectivity at the cellular level. These inhibitors when dosed to cynomolgus monkey are well-tolerated and inhibit circulating CTX-I levels (marker of bone resorption) by up to 95%. Moreover, duration of anti-resorptive activity exceeds plasma exposure, likely due to prolonged residence time in the targeted osteoclast cells. The high potency and prolonged efficacy duration in vivo together with excellent selectivity renders these candidate drugs highly attractive for clinical development. This includes the therapy areas of osteoporosis, osteoarthritis, rheumatoid arthritis and metastatic bone disease. The poster is available to access on our website under IR & Media/latest events/ASBMR For additional information, please contact Rein Piir, CFO & VP Investor Relations, Medivir +46 8 5468 3123 or +46 708 537 292. For more on Medivir, please see the company website:

About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Documents & Links